A PHASE II STUDY OF DEPSIPEPTIDE IN PTS W/ RELAPSED/REFRACTORY MULTI MYELOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是测试多肽治疗复发性/复发性多发性骨髓瘤的安全性和有效性。如果患者同意，我们还将测试患者的骨髓样本，以测试哪些基因会受到去脂肽的影响。在第1天、第8天和第15天，以13 mg/m2的速度通过外周静脉或中心静脉给药，持续4小时。周期将每28天重复一次，直到疾病进展、患者出现无法忍受的副作用或撤回同意。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test the safety and effectiveness of Depsipeptide as a treatment for patients with relapsed/refratory mutliple myeloma. If patients agree, we will also be testing samples of patients' bone marrow to test which genes, if any, will be affected by depsipeptide. Depsipeptide will be administered at 13mg/m2 over 4 hours on days 1, 8, and 15 through a peripheral IV or central line. Cycles will be repeated every 28 days until disease progression, patient experiences intolerable side effects, or withdraws consent.